Evidence map›Paper›PMID 26378448›Full record

ArticlePloS one2015

Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome.

Hiroyuki Shinchi, Nobuhiro Yuki, Hideharu Ishida, Koichi Hirata, Masahiro Wakao, Yasuo Suda

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hiroyuki ShinchiDepartment of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan.
Nobuhiro YukiDepartment of Neurology, Dokkyo Medical University, Tochigi 321-0293, Japan; Brain & Mind Research Institute, University of Sydney, Level 7, Building F, 94 Mallett Street, Camperdown, NSW 2050, Australia.
Hideharu IshidaDepartment of Applied Bioorganic Chemistry, Gifu University, Gifu 501-1193, Japan.
Koichi HirataDepartment of Neurology, Dokkyo Medical University, Tochigi 321-0293, Japan.
Masahiro WakaoDepartment of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan.
Yasuo SudaDepartment of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan; SUDx-Biotec Corporation, 1-42-1 Shiroyama, Kagoshima 890-0013, Japan.
Kagoshima University · JPDokkyo Medical University · JPGifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sugar chain binding antibodies have gained substantial attention as biomarkers due to their crucial roles in various disorders. In this study, we developed simple and quick detection method of anti-sugar chain antibodies in sera using our previously developed sugar chain-immobilized fluorescent nanoparticles (SFNPs) for the point-of-care diagnostics. Sugar chain structure on SFNPs was modified with the sugar moieties of the GM1 ganglioside via our original linker molecule to detect anti-GM1 antibodies. The structures and densities of the sugar moieties immobilized on the nanoparticles were evaluated in detail using lectins and sera containing anti-GM1 antibodies from patients with Guillain-Barré syndrome, a neurological disorder, as an example of disease involving anti-sugar chain antibodies. When optimized SFNPs were added to sera from patients with Guillain-Barré syndrome, fluorescent aggregates were able to visually detect under UV light in three hours. The sensitivity of the detection method was equivalent to that of the current ELISA method used for the diagnosis of Guillain-Barré syndrome. These results suggest that our method using SFNPs is suitable for the point-of-care diagnostics of diseases involving anti-sugar chain antibodies.

Indexed as

Antibodies, ImmobilizedAutoantibodiesCarbohydratesFluorescent Antibody TechniqueG(M1) GangliosideGuillain-Barre SyndromeHumansLectinsNanoparticlesPoint-of-Care SystemsAntibodies, ImmobilizedAutoantibodiesCarbohydratesG(M1) GangliosideLectins

Identifiers

PMID26378448
PMCPMC4574945
OpenAlexW2153436404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.